NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared for marketing Osmetech’s eSensor Warfarin Sensitivity Test, the London-based firm announced today.
 
The genetic test is used to aid physicians in identifying patients who are at risk for increased sensitivity to the blood-thinning drug warfarin. Osmetech submitted its application with the FDA for the test at the beginning of this year.
 
The firm said that the FDA also cleared its second-generation eSensor XT-8 molecular diagnostics platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.